Species |
Mouse |
Protein Construction |
PLAU/Upa (Gly21-Phe433) Accession # P06869 |
His |
Avi |
N-term |
|
C-term |
|
Conjugate |
Biotin |
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
49.00 kDa |
Apparent Molecular Weight |
Due to enzyme lysis and glycosylation, the protein migrates to 30-35 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. |
Synonyms |
PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.